argenx N.V.

RemeGen’s telitacicept, the world’s first approved fusion protein targeting B-cell lymphocyte stimulator/a proliferation inducing ligand (BLyS/APRIL), is looking increasingly likely to provide a stron

Cartesian Therapeutics is banking on both positive mid-stage data for Descartes-08 as well as a manufacturing process designed to cut down on logistical hurdles and toxicity in order to make its CAR-T

“Pipeline in a pill”-style drug development will be on display in April, when more than half of the user fee goal dates are for new indications on sometimes sprawling labels, as well as one novel biol

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from